Solving the problem of antimicrobial resistance: is a global approach necessary?

Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.

The European journal of health economics : HEPAC : health economics in prevention and care·2026

Self-reporting quality of life in mild-to-moderate Alzheimer's disease and Lewy body dementia: Comparing capability and health-focused measures using response process validation.

Social science & medicine (1982)·2026

Factors Associated with Changes in Capability-Wellbeing for Children and Young People of Secondary School Age During the First COVID-19 Lockdown.

Child indicators research·2026

How do older patients with advanced kidney disease, and their family members, understand kidney function and failure? A qualitative study.

BMC nephrology·2025

Understanding what matters to young people with life-limiting and life-threatening conditions: a qualitative study to inform the development of a young person end-of-life capability measure.

Social science & medicine (1982)·2025

'That's why I wanted him to go on dialysis' - a qualitative inductive thematic analysis of older patients' and their family members' perspectives on kidney failure treatment decision-making.

BMC nephrology·2025

Pharmacological targeting of GCN5/PCAF (KAT2A/B): Current drug discovery strategies and translational potential.

Drug discovery today·2026

Artificial intelligence agents and agentic artificial intelligence applied to precision medicine.

Drug discovery today·2026

China's drug discovery strategy: established targets, combination approaches, and small-molecule optimization.

Drug discovery today·2026

mRNA therapeutics for restoring immune tolerance in autoimmune diseases.

Drug discovery today·2026

Sustainable drug delivery systems: Biodegradable carriers for a carbon-neutral pharma future.

Drug discovery today·2026

Designing time-limited aryl hydrocarbon receptor drugs: A kinetic framework from the FICZ-CYP1A1 feedback axis.

Drug discovery today·2026

The narrowing prokaryote-eukaryote divide reveals a complexity spectrum.

Trends in microbiology·2026

Complete genome sequence of a novel Pseudomonas sp. GW-45 isolated from Antarctic Ardley cove showing DMSP degradation capability.

Marine genomics·2026

Transcriptomic and proteomic analyses of Weissella koreensis isolated from kimchi with different growth-limiting temperatures.

Food research international (Ottawa, Ont.)·2026

Cofactor F420 Tail Length Diversity in Specific Representatives of the Class Methanosarcinia During Acetoclastic and Methylotrophic Methanogenesis: Deciphering Structural Variations.

Anaerobe·2026

Type III secretion system diversity in the Pseudomonas fluorescens species complex.

The New phytologist·2026

Why are archaea not pathogenic? A hypothesis based on metabolism-habitat covariation.

mBio·2026

Related Experiment Videos

Solving the problem of antimicrobial resistance: is a global approach necessary?

Related Concept Videos

Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.

Self-reporting quality of life in mild-to-moderate Alzheimer's disease and Lewy body dementia: Comparing capability and health-focused measures using response process validation.

Factors Associated with Changes in Capability-Wellbeing for Children and Young People of Secondary School Age During the First COVID-19 Lockdown.

How do older patients with advanced kidney disease, and their family members, understand kidney function and failure? A qualitative study.

Understanding what matters to young people with life-limiting and life-threatening conditions: a qualitative study to inform the development of a young person end-of-life capability measure.

'That's why I wanted him to go on dialysis' - a qualitative inductive thematic analysis of older patients' and their family members' perspectives on kidney failure treatment decision-making.

Pharmacological targeting of GCN5/PCAF (KAT2A/B): Current drug discovery strategies and translational potential.

Artificial intelligence agents and agentic artificial intelligence applied to precision medicine.

China's drug discovery strategy: established targets, combination approaches, and small-molecule optimization.

mRNA therapeutics for restoring immune tolerance in autoimmune diseases.

Sustainable drug delivery systems: Biodegradable carriers for a carbon-neutral pharma future.

Designing time-limited aryl hydrocarbon receptor drugs: A kinetic framework from the FICZ-CYP1A1 feedback axis.

The narrowing prokaryote-eukaryote divide reveals a complexity spectrum.

Complete genome sequence of a novel Pseudomonas sp. GW-45 isolated from Antarctic Ardley cove showing DMSP degradation capability.

Transcriptomic and proteomic analyses of Weissella koreensis isolated from kimchi with different growth-limiting temperatures.

Cofactor F420 Tail Length Diversity in Specific Representatives of the Class Methanosarcinia During Acetoclastic and Methylotrophic Methanogenesis: Deciphering Structural Variations.

Type III secretion system diversity in the Pseudomonas fluorescens species complex.

Why are archaea not pathogenic? A hypothesis based on metabolism-habitat covariation.

Related Experiment Videos

Solving the problem of antimicrobial resistance: is a global approach necessary?

Related Concept Videos

Related Articles